Perils at mucosal front lines for HIV and SIV and their hosts

Nature Reviews Immunology

Volumn 5, Issue 10, 2005, Pages 783-792

  Haase, Ashley T ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

DISEASE TRANSMISSION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; RISK ASSESSMENT; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; FEMALE; HIV; HUMANS; IMMUNITY, MUCOSAL; LENTIVIRUS INFECTIONS; MUCOUS MEMBRANE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 25844482131     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1706     Document Type: Review

References (117)

1. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb. Mortal. Wkly Rep. 30, 305-308 (1981).
2. Pneumocystis pneumonia - Los Angeles. MMWR Morb. Mortal. Wkly Rep. 30, 250-252 (1981).
3. Joint United Nations Programme on HIV/AIDS & World Health Organization. AIDS Epidemic Update: 2004 (Joint United Nations Programme on HIV/AIDS, Geneva, 2004).
4. Annan, K. In Africa, AIDS has a woman's face. New York Times (New York) 9 (29 Dec 2002).
5. Haase, A. T. Pathogenesis of lentivirus infections. Nature 322, 130-136 (1986).
6. Anderson, R. M. & May, R. M. Infectious diseases of humans: dynamics and control (Oxford Univ. Press, New York, 1991).
7. Mowat, A. M. & Viney, J. L. The anatomical basis of intestinal immunity. Immunol. Rev. 156, 145-166 (1997).
8. Pope, M. & Haase, A. T. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nature Med. 9, 847-852 (2003).
9. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
10. Allen, T. M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390 (2000).
11. Goulder, P. J. & Watkins, D. I. HIV and SIV CTL escape: implications for vaccine design. Nature Rev. Immunol. 4, 630-640 (2004).
12. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
13. Price, D. A. et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl Acad. Sci. USA 94, 1890-1895 (1997).
14. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
15. Persaud, D., Zhou, Y., Siliciano, J. M. & Siliciano, R. F. Latency in human immunodeficiency virus type 1 infection: no easy answers. J. Virol. 77, 1659-1665 (2003).
16. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
17. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
18. Haase, A. T. et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274, 985-989 (1996).
19. Schacker, T. et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J. Infect. Dis. 181, 354-357 (2000).
20. Heath, S. L., Tew, J. G., Tew, J. G., Szakal, A. K. & Burton, G. F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744 (1995).
21. + T cells. Nature 417, 95-98 (2002).
22. + T cells in the gut lamina propria.
23. + memory T cells in all lymphoid tissues are infected (that is, viral-DNA positive) and then depleted, which is consistent with direct killing as the mechanism of depletion. Both activated, proliferating cells and 'resting' cells are infected, and the authors show that infection correlates with the amount of CCR5 mRNA in 'resting' cells.
24. + T cells.
25. + T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Gastroenterology 116, 1115-1123 (1999).
26. Schneider, T. et al. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut 37, 524-529 (1995).
27. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200, 761-770 (2004).
28. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200, 749-759 (2004).
29. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77, 11708-11717 (2003).
30. Lim, S. G. et al. Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin. Exp. Immunol. 92, 448-454 (1993).
31. Kahn, J. O. & Walker, B. D. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339, 33-39 (1998).
32. Lavreys, L. et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin. Infect. Dis. 30, 486-490 (2000).
33. Schacker, T. W., Hughes, J. P., Shea, T., Coombs, R. W. & Corey, L. Biological and virologie characteristics of primary HIV infection. Ann. Intern. Med. 128, 613-620 (1998).
34. Ho, D. D. et al. Primary human T-lymphotropic virus type III infection. Ann. Intern. Med. 103, 880-883 (1985).
35. Kinloch-de Loes, S. et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin. Infect. Dis. 17, 59-65 (1993).
36. Cooper, D. A. et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1, 537-540 (1985).
37. Miller, C. J. et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63, 4277-4284 (1989). Describes the non-human primate model of vaginal transmission of HIV, which is generally considered to be the most relevant model.
38. Miller, C. J. et al. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J. Virol. 68, 6391-6400 (1994).
39. Hendrickx, A. G. & Cukierski, M. A. Reproductive and developmental toxicology in nonhuman primates. Prog. Clin. Biol. Res. 235, 73-88 (1987).
40. Ma, Z., Lu, F. X., Torten, M. & Miller, C. J. The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin. Immunol. 100, 240-249 (2001).
41. Miller, C. J. & Lu, F. X. Anti-HIV and -SIV immunity in the vagina. Int. Rev. Immunol. 22, 65-76 (2003).
42. Embretson, J. et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-362 (1993).
43. Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358 (1993).
44. Tenner-Racz, K. et al. HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. Am. J. Pathol. 123, 9-15 (1986).
45. Reimann, K. A. et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Virol. 68, 2362-2370 (1994).
46. Fox, C. H. Lymphoid germinal centers are reservoirs of HIV infection and account for the apparent latency of infection. AIDS Res. Hum. Retroviruses 8, 756-758 (1992).
47. Reinhart, T. A. et al. Simian immunodeficiency virus burden in tissues and cellular compartments during clinical latency and AIDS. J. Infect. Dis. 176, 1198-1208 (1997).
48. Miller, C. J. et al. Propagation and dissemination of infection after vaginal transmission of SIV J. Virol. 79, 9217-9227 (2005). Documents small founder populations of infected cells at the point of entry following intravaginal inoculation with SIV, and describes the requirement for local proliferation and for continued seeding of distal lymphoid tissues to establish systemic infection. These findings point to opportunities to prevent systemic infection using microbicides or vaccines that target viral vulnerabilities at the earliest stages of infection at the point of entry.
49. Shattock, R. J. & Moore, J. P. Inhibiting sexual transmission of HIV-1 infection. Nature Rev. Microbiol. 1, 25-34 (2003).
50. + T cells. Science 286, 1353-1357 (1999). First paper to show the infection of resting cells with SIV and HIV in vivo.
51. Hu, J., Gardner, M. B. & Miller, C. J. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74, 6087-6095 (2000).
52. Gray, R. H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149-1153 (2001).
53. Cohn, M. A. et al. Chronic inflammation with increased human immunodeficiency virus (HIV) RNA expression in the vaginal epithelium of HIV-infected Thai women. J. Infect. Dis. 184, 410-417 (2001).
54. Serwadda, D. et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J. Infect. Dis. 188, 1492-1497 (2003).
55. Gray, R. H., Wawer, M. J., Sewankambo, N. & Serwadda, D. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350, 1780 (1997).
56. Martin, H. L. et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J. Infect. Dis. 180, 1863-1868 (1999).
57. Sewankambo, N. et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350, 546-550 (1997).
58. Van Damme, L. et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360, 971-977 (2002).
59. + memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl Acad. Sci. USA 87, 6058-6062 (1990).
60. + T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl Acad. Sci. USA 101, 5640-5645 (2004).
61. Stevenson, M., Stanwick, T. L., Dempsey, M. P. & Lamonica, C. A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560 (1990).
62. + T cells in vitro.
63. + T cells are infectible by human immunodeficiency virus but do not release virus after activation. J. Virol. 69, 5659-5665 (1995).
64. Spina, C. A., Guatelli, J. C. & Richman, D. D. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J. Virol. 69, 2977-2988 (1995).
65. Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
66. Popovic, M., Sarngadharan, M. G., Read, E. & Gallo, R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497-500 (1984).
67. + T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl Acad. Sci. USA 100, 1908-1913 (2003).
68. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
69. Pierson, T. et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J. Virol. 74, 7824-7833 (2000).
70. Korin, Y. D. & Zack, J. A. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J. Virol. 73, 6526-6532 (1999).
71. Zack, J. A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
72. Greene, W. C. & Peterlin, B. M. Charting HIV's remarkable voyage through the cell: basic science as a passport to future therapy. Nature Med. 8, 673-680 (2002).
73. Anton, P. A. et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14, 1761-1765 (2000).
74. Zeitz, M., Greene, W. C., Peffer, N. J. & James, S. P. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Gastroenterology 94, 647-655 (1988).
75. Reilly, C., Schacker, T., Haase, A. T., Wietgrefe, S. & Krason, D. The clustering of infected SIV cells in lymphatic tissue. J. Am. Stat. Assoc. 97, 943-954 (2002).
76. + T cells to apoptosis induced by HIV gp120.
77. Levine, A. D. & Fiocchi, C. Regulation of life and death in lamina propria T cells. Semin. Immunol. 13, 195-199 (2001).
78. Bu, P. et al. Apoptosis: one of the mechanisms that maintains unresponsiveness of the intestinal mucosal immune system. J. Immunol. 166, 6399-6403 (2001).
79. Boirivant, M. et al. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J. Clin. Invest. 98, 2616-2622 (1996).
80. De Maria, R. et al. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J. Clin. Invest. 97, 316-322 (1996).
81. Backhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I. Host-bacterial mutualism in the human intestine. Science 307, 1915-1920 (2005).
82. + T cells and the control of human immunodeficiency virus infection. J. Virol. 78, 10096-10103 (2004).
83. + T-cell loss in the gut that is described in references 25 and 51. The robust response in female reproductive tissues might be an encouraging sign that a vaccine-induced response at the earliest stages of infection at the point of entry might be able to contain infection there and prevent systemic infection.
84. Mothe, B. R. et al. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76, 875-884 (2002).
85. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
86. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
87. Kuroda, M. J. et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162, 5127-5133 (1999).
88. + T cells - rather than a result of the virus-specific immune response.
89. De Boer, R. J. & Perelson, A. S. Target cell limited and immune control models of HIV infection: a comparison. J. Theor. Biol. 190, 201-214 (1998).
90. Schwartz, E. J. et al. Effect of target cell availability on HIV-1 production in vitro. AIDS 16, 341-345 (2002).
91. Heise, C. et al. Human immunodeficiency virus infection of enterocytes and mononuclear cells in human jejunal mucosa. Gastroenterology 100, 1521-1527 (1991).
92. Heise, C., Vogel, P., Miller, C. J., Halsted, C. H. & Dandekar, S. Simian immunodeficiency virus infection of the gastrointestinal tract of rhesus macaques. Functional, pathological, and morphological changes. Am. J. Pathol. 142, 1759-1771 (1993).
93. Kotler, D. P., Gaetz, H. P., Lange, M., Klein, E. B. & Holt, P. R. Enteropathy associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 101, 421-428 (1984).
94. Kotler, D. P., Reka, S. & Clayton, F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig. Dis. Sci. 38, 1119-1127 (1993).
95. Ullrich, R. et al. Mucosal HIV infection. Pathobiology 66, 145-150 (1998).
96. Ullirch, R. et al. Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann. Intern. Med. 111, 15-21 (1989).
97. mac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. J. Virol. 78, 841-854 (2004).
98. Guy-Grand, D., DiSanto, J. P., Henchoz, P., Malassis-Seris, M. & Vassalli, P. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-γ, TNF) in the induction of epithelial cell death and renewal. Eur. J. Immunol. 28, 730-744 (1998).
99. Martin, C. A. & Panja, A. Cytokine regulation of human intestinal primary epithelial cell susceptibility to Fas-mediated apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G92-G104 (2002).
100. Zhang, L. et al. Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J. Virol. 78, 5520-5522 (2004).
101. Belkaid, Y. & Rouse, B. T. Natural regulatory T cells in infectious disease. Nature Immunol. 6, 353-360 (2005).
102. Maloy, K. J. & Powrie, F. Regulatory T cells in the control of immune pathology. Nature Immunol. 2, 816-822 (2001).
103. Mills, K. H. Regulatory T cells: friend or foe in immunity to infection? Nature Rev. Immunol. 4, 841-855 (2004).
104. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531-562 (2004).
105. Kornfeld, C. et al. Anti-inflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115, 1082-1091 (2005).
106. Andersson, J. et al. The prevalence of regulatory cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J. Immunol. 174, 3143-3147 (2005).
107. Veazey, R. S. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Med. 9, 343-346 (2003).
108. Lederman, M. M. et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485-487 (2004).
109. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164, 1602-1611 (2000).
110. mac239. J. Virol. 71, 1911-1921 (1997).
111. mac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and α interferon responses. J. Virol. 77, 3099-3118 (2003).
112. Crotty, S. et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75, 7435-7452 (2001).
113. Johnson, R. P. et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73, 4952-4961 (1999).
114. Joag, S. V. et al. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 72, 9069-9078 (1998).
115. Enose, Y. et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 298, 306-316 (2002).
116. Johnson, R. P. & Desrosiers, R. C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10, 436-443 (1998).
117. mac239-infected rhesus macaques, but not resistance to rechallenge. J. Med. Primatol. 32, 201-210 (2003).